Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [21] Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
    Castaneda, Carlos A.
    Mittendorf, Elizabeth
    Casavilca, Sandro
    Wu, Yun
    Castillo, Miluska
    Arboleda, Patricia
    Nunez, Teresa
    Guerra, Henry
    Barrionuevo, Carlos
    Dolores-Cerna, Ketty
    Belmar-Lopez, Carolina
    Abugattas, Julio
    Calderon, Gabriela
    De La Cruz, Miguel
    Cotrina, Manuel
    Dunstan, Jorge
    Gomez, Henry L.
    Vidaurre, Tatiana
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (05): : 387 - 394
  • [22] Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy
    Yu, Hong
    Xu, Li
    Yin, Songcheng
    Jiang, Jianlong
    Hong, Chunhong
    He, Yulong
    Zhang, Changhua
    CURRENT ONCOLOGY, 2022, 29 (09) : 6496 - 6507
  • [23] Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy
    Basaran, Derman
    Boerner, Thomas
    Suhner, Jessa
    Sassine, Dib
    Liu, Ying
    Grisham, Rachel N.
    Tew, William P.
    Gardner, Ginger J.
    Zivanovic, Oliver
    Sonoda, Yukio
    Roche, Kara Long
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Soff, Gerald A.
    Jewell, Elizabeth L.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 36 - 40
  • [24] Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Chen, Li
    Kong, Xiangyi
    Huang, Shaolong
    Su, Zhaohui
    Zhu, Mengliu
    Fang, Yi
    Zhang, Lin
    Li, Xingrui
    Wang, Jing
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
    Lee, Kytmg-Hun
    Keam, Bhumsuk
    Im, Seock-Ah
    Kim, Tae-Yong
    Han, Sae-Won
    Oh, Do-Youn
    Kim, Jee Hyun
    Lee, Se-Hoon
    Han, Wonshik
    Kim, Dong-Wan
    Kim, Tae-You
    Park, In Ae
    Noh, Dong-Young
    Heo, Dae Seog
    Bang, Yung-Jue
    JOURNAL OF BREAST CANCER, 2012, 15 (04) : 427 - 433
  • [26] Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes
    Kim, Jieun
    Han, Boo-Kyung
    Ko, Eun Young
    Ko, Eun Sook
    Choi, Ji Soo
    Park, Ko Woon
    EUROPEAN RADIOLOGY, 2022, 32 (06) : 4056 - 4066
  • [27] Locoregional therapy in breast cancer patients treated with neoadjuvant chemotherapy
    Murchison, Sonja
    Truong, Pauline
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 865 - 875
  • [28] Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy
    Bossuyt, Veerle
    Symmans, W. Fraser
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (10) : 3153 - 3161
  • [29] Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
    Zhu, Meizhen
    Yu, Yang
    Shao, Xiying
    Zhu, Liang
    Wang, Linbo
    CHEMOTHERAPY, 2020, 65 (3-4) : 101 - 109
  • [30] The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
    Kantor, Olga
    Bao, Jean
    Jaskowiak, Nora
    Yao, Katherine
    Tseng, Jennifer
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (02) : 352 - 358